Business
MaaT Pharma Announces Promising Final Data Readout for Phase 1b Evaluating MaaT033 in Amyotrophic Lateral Sclerosis (ALS)
LYON, France, May 12, 2025--MaaT Pharma Announces Promising Final Data Readout for Phase 1b Evaluating MaaT033 in Amyotrophic Lateral Sclerosis (ALS)
About this update from Maat Pharma
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":442,"height":480,"url":"https://media.zenfs.com/en/business-wire.com/e590cd1ff2213e1c28b6bf10fb78a6ff"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Uy0R7oKafKkHAuQ01UrxIw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTc2NjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/e590cd1ff2213e1c28b6bf10fb78a6ff","width":442,"height":480}},"lazy":false},{"type":"text","content":"LYON, France, May 12, 2025--(BUSINESS WIRE)--Regulatory News:","length":61,"tagName":"p"},{"type":"text","content":"MaaT Pharma (EURONEXT: MAAT – the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer through immune modulation, announced additional findings following full data readout for the exploratory single-arm, open-label Phase 1b clinical trial named IASO (NCT05889572) evaluating MaaT033 in Amyotrophic Lateral Sclerosis (ALS).","length":461,"tagName":"p"},{"type":"text","content":"In November 2024, the Company announced that the trial had met its primary endpoint assessing the safety and tolerability of MaaT033 with multiple doses, following the independent Data Safety and Monitoring Board (DSMB) conclusion. As a reminder, the exploratory Phase 1b trial enrolled a total of 15 participants across two centers in France Hôpital de la Pitié-Salpêtrière – AP-HP and the University Hospital of Lille. An external Scientific Advisory Committee took place at the end of March 2025 to review the full data. Below are the key takeaways from the Committee’s review:","length":580,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"MaaT033 demonstrated a favorable safety and tolerability profile, supported by biomarker and microbiome analyses.","length":113,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"A rapid and sustained engraftment of bacterial species from MaaT033 was observed, mostly occurring within the first month and maintained during the 1-month follow-up period.","length":173,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"A slower rate of disease progression (based on ALSFRS-R slopes) was noted to be interpreted with caution given the shor...